Skip to main content
PMC home page
Food Science and Biotechnology logoLink to Food Science and Biotechnology
. 2016 Jun 30;25(3):911–914. doi: 10.1007/s10068-016-0149-9

Effect of supplementation of low-molecular-weight chitosan oligosaccharide, GO2KA1, on postprandial blood glucose levels in healthy individuals following bread consumption

Yu-Ri Kang 4, Hwang-Yong Choi 4, Jung-Yun Lee 4, Soo-In Jang 4, Jung-Bae Oh 1, Justin S Kim 1, Jong-Wook Lee 2, Sung-Hoon Jo 3, Kyoung-Soo Ha 3, Mee-Sook Lee 4, Young-Cheul Kim 1, Emmanouil Apostolidis 3, Young-In Kwon 4,✉
PMCID: PMC6049137  PMID: 30263353

Abstract

The effect of chitosan oligosaccharide (GO2KA1) administration on postprandial blood glucose levels of subjects with normal blood glucose levels was evaluated following bread consumption. Postprandial blood glucose levels were determined for 2 h after bread ingestion with or without 500 mg of GO2KA1. GO2KA1 significantly lowered the mean, maximum, and minimum levels of postprandial blood glucose at 30 min after the meal. Postprandial blood glucose levels were decreased by about 25% (from 155.11±13.06 to 138.50±13.59, p<0.01) at 30 min when compared to control. Furthermore, we observed that the area under the concentration-time curve (AUCt) was decreased by about 6% (from 255.46±15.43 to 240.15±14.22, p<0.05) and the peak concentration of blood glucose (C max) was decreased by about 11% (from 157.94±10.90 to 140.61±12.52, p<0.01) when compared to control. However, postprandial the time to reach C max (Tmax) levels were the same as those found in control. Our findings suggest that GO2KA1 limits the increase in postprandial blood glucose levels following bread consumption.

Keywords: chitosan oligosaccharide, GO2KA1, anti-hyperglycemic effects, healthy individuals, postprandial hyperglycemia

References

  • 1.American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35:S64–S71. doi: 10.2337/dc12-s064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Centers for Disease ControlPrevention. Diabetes Report Card 2014. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2015. [Google Scholar]
  • 3.James PB, Theodore JT, Edward WG, Lawrence EB, David FW. Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metrics. 2010;8:29. doi: 10.1186/1478-7954-8-29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Adam GT, Christian H, Wolfgang R, Eric JB, Mika K. Prediabetes: A high-risk state for diabetes development. Lancet. 2012;379:2279–2290. doi: 10.1016/S0140-6736(12)60283-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.David MN, Rury RH, John BB, Robert S, Mayer BD, Bernard Z, Ele F. Medical management of hyperglycemia in Type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193–203. doi: 10.2337/dc08-9025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Derosa G, Maffioli P. a-Glucosidase inhibitors and their use in clinical practice. Arch. Med. Sci. 2012;8:899–906. doi: 10.5114/aoms.2012.31621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.No HK, Park NY, Lee SH, Samuel PM. Antibacterial activity of chitosans and chitosan oligomers with different molecular weights. Int. J. Food Microbiol. 2002;74:65–72. doi: 10.1016/S0168-1605(01)00717-6. [DOI] [PubMed] [Google Scholar]
  • 8.Koji H, Mikio I. Action of low molecular weight chitosan in genetically obese diabetic KK-Ay Mice. Biol. Pharm. Bull. 2002;25:188–192. doi: 10.1248/bpb.25.188. [DOI] [PubMed] [Google Scholar]
  • 9.Lee H-W, Park Y-S, Choi J-W, Yi S-Y, Shin W-S. Antidiabetic effects of chitosan oligosaccharides in neonatal streptozotocin-induced noninsulin-dependent diabetes mellitus in rats. Biol. Pharm. Bull. 2003;26:1100–1103. doi: 10.1248/bpb.26.1100. [DOI] [PubMed] [Google Scholar]
  • 10.Cynthia MG, Jessa M, Robert HJ, John W, Daniel DG. Cholesterol reduction by glucomannan and chitosan is mediated by changes in cholesterol absorption and bile acid and fat excretion in rats. J. Nutr. 2000;130:2753–2759. doi: 10.1093/jn/130.11.2753. [DOI] [PubMed] [Google Scholar]
  • 11.Qin C, Du Y, Xiao L, Li Z, Gao X. Enzymic preparation of water-soluble chitosan and their antitumor activity. Int. J. Biol. Macromol. 2002;31:111–117. doi: 10.1016/S0141-8130(02)00064-8. [DOI] [PubMed] [Google Scholar]
  • 12.Qi L, Xu Z. In vivo antitumor activity of chitosan nanoparticles. Bioorg. Med. Chem. Lett. 2006;16:4243–4245. doi: 10.1016/j.bmcl.2006.05.078. [DOI] [PubMed] [Google Scholar]
  • 13.Yen MT, Yang JH, Mau JL. Antioxidant properties of chitosan from crab shells. Carbohyd. Polym. 2008;74:840–844. doi: 10.1016/j.carbpol.2008.05.003. [DOI] [Google Scholar]
  • 14.Tao S, Dongxiang Z, Junlin X, Fang M. Preparation of chitosan oligomers and their antioxidant activity. Eur. Food Res. Technol. 2007;225:451–456. doi: 10.1007/s00217-006-0439-1. [DOI] [Google Scholar]
  • 15.Jo SH, Ha KS, Moon KS, Kim JG, Oh CG, Kim YC, Apostolidis E, Kwon YI. Molecular weight dependent glucose lowering effect of low molecular weight chitosan oligosaccharide (GO2KA1) on postprandial blood glucose level in SD rats model. Int. J. Mol. Sci. 2013;14:14214–14224. doi: 10.3390/ijms140714214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Jo SH, Ha KS, Lee JW, Kim YC, Apostolidis E, Kwon YI. The reduction effect of low molecular weight chitosan oligosaccharide (GO2KA1) on postprandial blood glucose levels in healthy individuals. Food Sci. Biotechnol. 2014;23:971–973. doi: 10.1007/s10068-014-0131-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Food Science and Biotechnology are provided here courtesy of Springer

RESOURCES